Systemic sclerosis-related interstitial lung disease (SSc-ILD) is the leading cause of death in
SSc. In this study, we aimed to describe the baseline severity and evolution of forced vital …

Objective. Clinically meaningful change in systemic sclerosis (SSc) related interstitial lung
(SSc-ILD) disease is unknown. The aim of this study was to quantify change in pulmonary …

Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic
sclerosis (SSc). We performed a systematic review to characterise the use and validation of …

Rationale: Previous studies have suggested that interstitial lung disease (ILD) progresses
most rapidly early in the course of systemic sclerosis–associated (SSc)-ILD, and that SSc …

Objectives The aim of this study was to identify risk factors of percent predicted forced vital
capacity (ppFVC) decline in patients with SSc-associated interstitial lung disease (SSc-ILD) …

Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ
systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in …

Background Systemic sclerosis (SSc) is a heterogeneous disease with frequently associated
interstitial lung disease (SSc-ILD). We aimed to determine the prognostic potential of …

Classification of SSc-ILD has shifted to a personalized approach that considers an individual
patient's probability of progressive disease through identification of risk factors …

Rationale: Interstitial lung disease (ILD) represents a major challenge in systemic sclerosis
(SSc), but there are no precise, population-based data on its overall impact, limiting …

Objective In patients with systemic sclerosis (SSc), we investigated composite serum
biomarker panels for the diagnosis and risk stratification of SSc–associated interstitial lung …